Neurocrine Biosciences, Inc.
General ticker "NBIX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $13.1B
Neurocrine Biosciences, Inc. does not follow the US Stock Market performance with the rate: -12.0%.
Estimated limits based on current volatility of 1.7%: low 134.71$, high 139.27$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [96.21$, 150.66$]
- 2024-12-30 to 2025-12-30 estimated range: [106.03$, 164.40$]
Financial Metrics affecting the NBIX estimates:
- Positive: Non-GAAP EPS, $ of 2.42 > 2.29
- Negative: Investing cash flow per share, $ of -4.78 <= -3.48
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
- Positive: 9.05 < Operating profit margin, % of 13.30
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term NBIX quotes
Long-term NBIX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $1,133.50MM | $1,488.70MM | $1,887.10MM |
| Operating Expenses | $1,031.00MM | $1,239.70MM | $1,636.20MM |
| Operating Income | $102.50MM | $249.00MM | $250.90MM |
| Non-Operating Income | $-1.10MM | $-35.10MM | $81.20MM |
| Interest Expense | $25.80MM | $7.10MM | $4.60MM |
| R&D Expense | $328.10MM | $463.80MM | $565.00MM |
| Income(Loss) | $101.40MM | $213.90MM | $332.10MM |
| Taxes | $11.80MM | $59.40MM | $82.40MM |
| Profit(Loss) | $89.60MM | $154.50MM | $249.70MM |
| Stockholders Equity | $1,374.00MM | $1,707.80MM | $2,232.00MM |
| Inventory | $30.50MM | $35.10MM | $38.30MM |
| Assets | $2,072.50MM | $2,368.70MM | $3,251.40MM |
| Operating Cash Flow | $256.50MM | $339.40MM | $389.90MM |
| Capital expenditure | $23.40MM | $16.50MM | $28.30MM |
| Investing Cash Flow | $-130.20MM | $-177.10MM | $-467.10MM |
| Financing Cash Flow | $27.40MM | $-234.30MM | $65.30MM |
| Earnings Per Share* | $0.95 | $1.61 | $2.56 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.